deferoxamine has been researched along with Leukemia, Myeloid in 11 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Leukemia, Myeloid: Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deferoxamine is a hydroxylamine which binds ferric ions to form a highly stable complex." | 1.27 | Inhibition of proliferation of human leukaemic cell populations by deferoxamine. ( Foa, P; Lombardi, L; Maiolo, AT; Polli, EE; Villa, L, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (36.36) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaloyannidis, P | 1 |
| Yannaki, E | 1 |
| Sakellari, I | 1 |
| Bitzioni, E | 1 |
| Athanasiadou, A | 1 |
| Mallouri, D | 1 |
| Anagnostopoulos, A | 1 |
| Song, S | 1 |
| Christova, T | 1 |
| Perusini, S | 1 |
| Alizadeh, S | 1 |
| Bao, RY | 1 |
| Miller, BW | 1 |
| Hurren, R | 1 |
| Jitkova, Y | 1 |
| Gronda, M | 1 |
| Isaac, M | 1 |
| Joseph, B | 1 |
| Subramaniam, R | 1 |
| Aman, A | 1 |
| Chau, A | 1 |
| Hogge, DE | 1 |
| Weir, SJ | 1 |
| Kasper, J | 1 |
| Schimmer, AD | 1 |
| Al-awar, R | 1 |
| Wrana, JL | 1 |
| Attisano, L | 1 |
| Jiang, Y | 1 |
| Xue, ZH | 1 |
| Shen, WZ | 1 |
| Du, KM | 1 |
| Yan, H | 1 |
| Yu, Y | 1 |
| Peng, ZG | 1 |
| Song, MG | 1 |
| Tong, JH | 1 |
| Chen, Z | 1 |
| Huang, Y | 1 |
| Lübbert, M | 1 |
| Chen, GQ | 1 |
| Fukuchi, K | 1 |
| Tomoyasu, S | 1 |
| Tsuruoka, N | 1 |
| Gomi, K | 1 |
| Leardi, A | 1 |
| Caraglia, M | 1 |
| Selleri, C | 1 |
| Pepe, S | 1 |
| Pizzi, C | 1 |
| Notaro, R | 1 |
| Fabbrocini, A | 1 |
| De Lorenzo, S | 1 |
| Musicò, M | 1 |
| Abbruzzese, A | 1 |
| Bianco, AR | 1 |
| Tagliaferri, P | 1 |
| Dellinger, B | 1 |
| Pryor, WA | 1 |
| Cueto, R | 1 |
| Squadrito, GL | 1 |
| Hegde, V | 1 |
| Deutsch, WA | 1 |
| Poot, M | 1 |
| Hoehn, H | 1 |
| Becton, DL | 1 |
| Roberts, B | 1 |
| Rouault, T | 1 |
| Rao, K | 1 |
| Harford, J | 1 |
| Mattia, E | 1 |
| Klausner, RD | 1 |
| Satyamoorthy, K | 1 |
| Chitnis, MP | 1 |
| Basrur, VS | 1 |
| Advani, SH | 1 |
| Foa, P | 1 |
| Maiolo, AT | 1 |
| Lombardi, L | 1 |
| Villa, L | 1 |
| Polli, EE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 1 Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy[NCT00990587] | Phase 1 | 20 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for deferoxamine and Leukemia, Myeloid
| Article | Year |
|---|---|
Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers.
Topics: Acute Disease; Administration, Oral; Benzoates; beta Catenin; Cell Line, Tumor; Cell Proliferation; | 2011 |
10 other studies available for deferoxamine and Leukemia, Myeloid
| Article | Year |
|---|---|
The impact of desferrioxamine postallogeneic hematopoietic cell transplantation in relapse incidence and disease-free survival: a retrospective analysis.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Deferoxamine; Disease-Free Surviv | 2010 |
Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1 alpha that augments transcriptional activity of CCAAT/enhancer-binding protein-alpha.
Topics: Acute Disease; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Cell Line, Tumor; Core Bi | 2005 |
Iron deprivation-induced apoptosis in HL-60 cells.
Topics: Apoptosis; Deferoxamine; DNA, Neoplasm; Humans; Iron Deficiencies; Leukemia, Myeloid; Tumor Cells, C | 1994 |
Desferioxamine increases iron depletion and apoptosis induced by ara-C of human myeloid leukaemic cells.
Topics: Acute Disease; Antidotes; Antimetabolites, Antineoplastic; Apoptosis; Cell Division; Cytarabine; Def | 1998 |
Role of free radicals in the toxicity of airborne fine particulate matter.
Topics: Air Pollutants; Bacteriophages; Catalase; Comet Assay; Deferoxamine; DNA Damage; DNA, Superhelical; | 2001 |
Correspondence Re: David L. Becton and Barbara Roberts. Antileukemic effects of deferoxamine on human myeloid leukemia cell lines. Cancer Res., 49:4809-4812, 1989.
Topics: Cell Division; Cell Line; Deferoxamine; Free Radicals; Humans; Leukemia, Myeloid; Tumor Cells, Cultu | 1990 |
Antileukemic effects of deferoxamine on human myeloid leukemia cell lines.
Topics: Antineoplastic Agents; Cell Division; Deferoxamine; DNA, Neoplasm; Drug Screening Assays, Antitumor; | 1989 |
Hemin, chelatable iron, and the regulation of transferrin receptor biosynthesis.
Topics: Cell Line; Deferoxamine; Heme; Humans; Iron; Kinetics; Leukemia, Myeloid; Receptors, Cell Surface; R | 1985 |
Potentiation of hydroxyurea cytotoxicity in human chronic myeloid leukemia cells by iron-chelating agent.
Topics: 2,2'-Dipyridyl; Antineoplastic Combined Chemotherapy Protocols; Deferoxamine; Drug Synergism; Edetic | 1986 |
Inhibition of proliferation of human leukaemic cell populations by deferoxamine.
Topics: Cell Division; Cell Line; Deferoxamine; DNA; Humans; Interphase; Leukemia; Leukemia, Lymphoid; Leuke | 1986 |